NurExone Biologic Inc. NRX.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Israel · nurexone.com
NurExone Biologic Inc. is a biopharmaceutical company developing exosome-based therapies for spinal cord injuries and central nervous system indications. Its flagship ExoPTEN therapy has received FDA Orphan Drug Designation for acute spinal cord injury treatment, with preclinical studies demonstrating structural repair and full motor function recovery. The company is headquartered in Haifa, Israel, and is listed on the TSX Venture Exchange, Frankfurt Stock Exchange, and OTCQB.
Key ratios
ReturnOnAssets TTM -1.21
ReturnOnAssets 2025 -1.21
ReturnOnAssets 2024 -1.36
ReturnOnAssets 2023 -0.92
ReturnOnEquity TTM -2.83
ReturnOnEquity 2025 -2.83
ReturnOnEquity 2024 -5.17
ReturnOnEquity 2023 -3.19
Recent news
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
2026-07-30 · GlobeNewswire
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
2026-07-28 · GlobeNewswire
NurExone Subsidiary Exo-Top Signs MOU for Naïve Exosome Distribution in Mexico
2026-06-24 · GlobeNewswire
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-06-01 · GlobeNewswire
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
2026-05-14 · GlobeNewswire